




RealRate

PHARMACEUTICAL 2021

Actinium Pharmaceuticals Inc.
Rank 164 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



RealRate

PHARMACEUTICAL 2021

Actinium Pharmaceuticals Inc. Rank 164 of 409



The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 256% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is -64%, being 291% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	64,925
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,767
Liabilities, Non-Current	0
Other Assets	1,160
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	311
Other Net Income	178
Property and Equipment	312
Research and Development	16,085
Revenues	0
Selling, General and Administrative Expense	6,308

Output Variable	Value in 1000 USD
Assets	66,397
Liabilities	5,078
Expenses	22,393
Stockholders Equity	61,319
Net Income	-22,215
Comprehensive Net Income	-22,215
Economic Capital Ratio	-64%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai